98%
921
2 minutes
20
The unexpected emergence and spread of coronavirus disease 2019 (COVID-19) has been pandemic, with long-lasting effects, and unfortunately, it does not seem to have ended. Integrating advanced planning, strong teamwork, and clinical management have been both essential and rewarding during this time. Understanding the new concepts of this novel disease and accommodating them into clinical practice is an ongoing process, ultimately leading to advanced and highly specific treatment modalities. We conducted a literature review through PubMed, Europe PMC, Scopus, and Google Scholar to incorporate the most updated therapeutic principles. This article provides a concise and panoramic view of the cohort of critically ill patients admitted to the intensive care unit. We conclude that COVID-19 management includes low tidal volume ventilation, early proning, steroids, and a high suspicion for secondary bacterial/fungal infections. Lung ultrasound is emerging as a promising tool in assessing the clinical response. Managing non-clinical factors such as staff burnout, communication/consent issues, and socio-emotional well-being is equally important.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940099 | PMC |
http://dx.doi.org/10.4266/acc.2020.00864 | DOI Listing |
Infect Dis Ther
September 2025
School of Biomedical Sciences, The Chinese University of Hong Kong (CUHK), Hong Kong SAR, China.
Introduction: The high mortality of Coronavirus Disease 2019 (COVID-19) highlights the need for safe and effective antiviral treatment. Small molecular antivirals (remdesivir, molnupiravir, nirmatrelvir/ritonavir) and immunomodulators (baricitinib, tocilizumab) have been developed or repurposed to suppress viral replication and ameliorate cytokine storms, respectively. Despite U.
View Article and Find Full Text PDFObjectives: This study aimed to analyse the number of myocardial infarction (MI) admissions during the COVID-19 lockdown periods of 2020 and 2021 (March 15th to June 15th) and compare them with corresponding pre-pandemic period in 2019. The study also evaluated changes in critical treatment intervals: onset to door (O2D), door to balloon (D2B) and door to needle (D2N) and assessed 30-day clinical outcomes. This study examined MI care trends in India during the COVID-19 lockdown period, irrespective of patients' COVID-19 infection status.
View Article and Find Full Text PDFChest
September 2025
Child and Maternal Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia; School of Nursing and Midwifery, Charles Darwin University, Darwin, Northern Territory, Australia.
Background: Managing bronchiectasis exacerbations is a priority for patients/parents/caregivers of children with bronchiectasis, yet evidence-based strategies among the pediatric population remain limited.
Research Question: Does the use of a personalized, written bronchiectasis action management plan (BAMP), compared to standard care, reduce non-scheduled doctor visits among children/adolescents with chronic suppurative lung disease (CSLD)/bronchiectasis?
Study Design And Methods: Our multicenter, double-blind, superiority, randomized controlled trial enrolled children from three Australian respiratory departments between June 2018 and December 2020. Children/adolescents aged <19 years with CSLD/bronchiectasis were randomized to receive a personalized BAMP (intervention) or standard care (controls).
Brain Behav Immun
September 2025
Department of Rehabilitation Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA; MH Neuropsychology, Atlanta, GA 30339, USA.
Int J Infect Dis
September 2025
Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS AziendaOspedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Background: Patients with B-cell malignancies are at high risk of persisting SARS-CoV-2 infection, which may delay oncologic treatments and increase morbidity. We aimed to assess risk factors for persisting infection in this population.
Methods: We conducted a multicenter retrospective study across five tertiary hospitals between January 1, 2022, and January 1, 2023.